Commissioner Johansson acknowledges value of EMCDDA analysis in informing drug policy
European Commissioner for Home Affairs Ylva Johansson paid her first visit to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) today during a day of events relating to the fight against organised crime.
European Commission proposes to control two harmful new psychoactive substances
Today, the European Commission has proposed to control two harmful new psychoactive substances (NPS) across the European Union. The substances in question — MDMB-4en-PINACA and 4F-MDMB-BICA — are both synthetic cannabinoids, which have been raising health concerns in Europe (1).
Maximising access to drug treatment while minimising diversion of medications — new EMCDDA report looks at striking the balance
Opioid substitution treatment (OST) is a key evidence-based tool used to manage opioid dependence and improve related health and social consequences. Yet increasing reports of the diversion and misuse of the controlled drugs used in this treatment in Europe are a cause for concern.
Bursaries for students from European Neighbourhood Policy countries for the 2021 European Drugs Winter and Summer Schools
Professionals, academics or experts from European Neighbourhood Policy (ENP) countries (1) will have an opportunity to participate in the European Drugs Winter and Summer Schools this year, thanks to 10 bursaries being offered through the EU4Monitoring Drugs (EU4MD
Bursaries for Western Balkan students for the 2021 European Drugs Winter School
Professionals, academics and experts from the Western Balkan region will have an opportunity to participate in the first European Drugs Winter School (EDWS) this year, thanks to six bursaries being offered through the EMCDDA Instrument for Pre-accession Assistance project (
EMCDDA releases study findings on the impact of COVID-19 on drug markets, use and services in the southern ENP region
The emergence of new drug trafficking routes, the reduced availability of drug-related health services and the adaptation of drug treatment protocols during the COVID-19 pandemic are among the findings highlighted today in a new EMCDDA report: